CryositeASX:CTE 51 Days Payable is 78.73 as of Dec. 2025, which is 109% above its 10-year median of 37.63. GuruFocus rates ASX:CTE with a GF Score™ of 51/100 and a GF Value™ of A$0.94 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Cryosite ranks better than 54.74% on this metric.
Cryosite's average Accounts Payable for the
six
months ended in Dec. 2025 was A$1.37 Mil. Cryosite's Cost of Goods Sold for the
six
months ended in Dec. 2025 was A$3.19 Mil.
Hence, Cryosite's Days Payable for the
six
months ended in Dec. 2025 was 78.73.
The historical rank and industry rank for Cryosite's Days Payable or its related term are showing as below:
ASX:CTE'
s Days Payable Range Over the Past 10 Years
Min: 15.97 Med: 37.63 Max: 81.85
Current: 81.85
During the past 13 years, Cryosite's highest Days Payable was 81.85. The lowest was 15.97. And the median was 37.63.
ASX:CTE's Days Payable is ranked better than 54.74% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.275
vs ASX:CTE: 81.85
Cryosite's Days Payable
increased
from Dec. 2024 (74.86) to Dec. 2025 (78.73).
It may suggest that Cryositedelayed paying its suppliers.
Cryosite Days Payable Related Terms
Cryosite Days Payable Historical Data
* Premium members only.
The historical data trend for Cryosite's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CTE vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Cryosite's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cryosite Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cryosite's Days Payable distribution charts can be found below:
* The bar in red indicates where Cryosite's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Cryosite's Days Payable for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cryosite (ASX:CTE) has a Days Payable of 78.73 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cryosite and its competitors. This is 109% above median its historical median of 37.63. Over the past decade, Cryosite's Days Payable has ranged from 15.97 to 81.85. According to the industry distribution chart, Cryosite ranks #86 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 45.3%.
Is Cryosite's Days Payable too high?
Cryosite's current Days Payable of 78.73 is 109% above median its 10-year median of 37.63. Over the past 10 years, this metric has ranged from a low of 15.97 to a high of 81.85. The Medical Diagnostics & Research industry median Days Payable is 67.28. Cryosite's value of 78.73 is 17% above this industry median. Based on the distribution chart, Cryosite ranks #86 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Cryosite has a GF Score™ of 51/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Cryosite's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cryosite ranks #86 out of 190 companies for Days Payable. This puts Cryosite in the upper half of its industry. The industry median Days Payable is 67.28. Cryosite's value of 78.73 is 17% above this benchmark. Historically, Cryosite's own Days Payable has ranged from 15.97 to 81.85 over the past decade. While the company's 10-year median is 37.63 vs. the industry median of 67.28, Cryosite has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 67.28, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cryosite's current Days Payable of 78.73 is 17% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Cryosite and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 67.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cryosite's current Days Payable is 78.73, which is 109% above median its own 10-year median of 37.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryosite stock overvalued right now?
Based on GuruFocus' analysis, Cryosite (ASX:CTE) is currently considered Modestly Overvalued. The stock's GF Value™ is A$0.94, compared to a current price of A$1.15 — trading 22.3% above its estimated fair value. The current Days Payable is 78.73, which is 109% above median its 10-year median of 37.63 and 17% above the Medical Diagnostics & Research industry median of 67.28. Cryosite's overall GF Score™ is 51/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Cryosite (ASX:CTE), the current Days Payable is 78.73 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cryosite (ASX:CTE) Overvalued in 2026?
Based on GuruFocus' analysis, Cryosite stock appears to be overvalued.
The current stock price of A$1.15 is trading 22.3% above its estimated GF Value™ of A$0.94.
GuruFocus considers Cryosite to be Modestly Overvalued.
Key valuation signals for ASX:CTE:
Days Payable: 78.73 (109% above median its 10-year median of 37.63)
GF Value™: A$0.94 vs. price of A$1.15 (22.3% above fair value)
Industry Position: 17% above the Medical Diagnostics & Research median (#86 of 190)
No single metric tells the full story. See the ASX:CTE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cryosite Ltd provides an integrated clinical trial logistics service, biological storage and sample management service, including the storage of cord blood stem cells for private use. It supports a diverse portfolio of materials, including Good Manufacturing Practice (GMP) clinical trial products, Australian Register of Therapeutic Goods (ARTG) approved medicines, biologics, Research and Development materials, and medical devices, among others. The group's operating segments are: Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord blood. The majority of its revenue is generated from the Ambient, cold, and frozen segment, which provides storage and distribution of small-molecule drugs and related products requiring ambient, refrigerated, or frozen conditions.
51GF Score
Get the complete analysis for ASX:CTE
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CTE has been successfully added to your 
